iRhythm Technologies Inc. (IRTC) shares are soaring 12.67% in pre-market trading on Friday, following the company's impressive third-quarter results and a wave of analyst upgrades. The medical technology company, which specializes in cardiac monitoring, reported better-than-expected earnings and raised its full-year guidance, sparking renewed investor confidence.

For the third quarter, iRhythm reported an adjusted net loss of $0.06 per share, significantly narrower than the $1.26 loss per share in the same period last year and beating analyst expectations of a $0.28 loss. Revenue climbed to $192.9 million, up from $147.5 million a year earlier and surpassing the FactSet consensus estimate of $184.8 million. In light of these strong results, the company raised its full-year 2025 revenue guidance to $735-$740 million, up from the previous forecast of $720-$730 million.

The positive earnings report has triggered a flurry of analyst upgrades. JPMorgan raised its price target to $240 from $190, while Needham increased its target to $244 from $193. Other firms including Citigroup, Oppenheimer, and Truist Securities also significantly raised their price targets, reflecting growing optimism about iRhythm's growth prospects. This surge of positive sentiment from Wall Street is likely fueling the stock's pre-market rally, as investors anticipate continued strong performance from the cardiac monitoring technology leader.